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Abstract
Retinoic acid (RA) receptor (RAR) 2 has been shown
to be underexpressed in human breast cancer cells,
including MCF-7 cells, and recent reports have
suggested that hypermethylation of the RAR2
promoter and 5-UTR is the underlying cause. Here we
show that RAR2 is also underexpressed in MCF-7
breast cancer cells, at both the message and the
protein level, relative to normal or nontumorigenic
breast epithelial cells. Bisulfite sequencing of the
CpG island in the RAR2 promoter revealed highly
penetrant and uniform cytosine methylation in MCF-7
cells. Pretreatment with the DNA methyltransferase
inhibitor, azacytidine, followed by treatment with RA
and a histone deacetylase inhibitor, trichostatin A,
resulted in partial promoter demethylation and RAR2
induction, which strongly suggested that promoter
hypermethylation is responsible for RAR2
underexpression. We compared the outcome of
ectopic expression in MCF-7 cells of matched levels
of RAR2 and RAR2. On the basis of a clonogenic
assay, RAR2 displayed ligand-dependent growth-
suppressive activity similar to that of RAR2; thus,
10 and 20 nM RA inhibited clonogenic growth by 52
and 80%, respectively, in RAR2-transfected cells
compared with 75 and 77%, respectively, in RAR2-
transfected cells. We conclude that the silencing of
the RAR2 promoter by hypermethylation may play a
contributory role in the dysregulation of RA signaling in
mammary tumorigenesis.
Introduction
Most of the biological effects of vitamin A are mediated by
vitamin A metabolites that bind and activate members of the
all-trans-RA
3 and “retinoid X” (9-cis-RA) receptors (RARs
and RXRs, respectively), which belong to the superfamily of
ligand-dependent transcription factors. RA regulation of
gene transcription is optimally mediated by heterodimers
formed between any of the three known RARs( , , ) and
any of the three known RXR genes (, , ). Biological pro-
cesses dependent on the activity of RXR-RAR heterodimers
include mammalian development, as demonstrated by ex-
tensive gene targeting studies in the mouse (reviewed in Ref.
1), and cancer, as demonstrated by the role of RAR in the
pathogenesis and therapy of acute promyelocytic leukemia
(reviewed in Ref. 2) and as suggested by the chemopreven-
tive activity of retinoids toward solid tumors (reviewed in Ref.
3). Particularly interesting in connection to the possible role
of RARs in regulating epithelial carcinogenesis is the recent
observation that RAR regulates branching morphogenesis
in the lung (4).
Another line of investigation suggestive of a role of RARs
in the regulation of epithelial carcinogenesis is the down-
regulation of RAR gene expression in cancer. In particular,
the expression of RAR2, which is normally induced by RA
through the DR5 response element in its promoter (5), has
been shown to be down-regulated in a wide range of cancer
cell types and tissues (6–10). Several recent reports have
argued that the down-regulation of RAR2 in cancer is sec-
ondary to hypermethylation of the gene (11–14). The finding
that cancer cells that display no detectable RAR message
usually retain RAR and RAR expression underlies the in-
terest in the loss of RAR expression in cancer. However, the
growth-suppressive activity of RAR2 (15–17) is not unique,
because other RARs, such as RAR1, are also growth sup-
pressive (18, 19). Furthermore, several authors have demon-
strated that the selective activation of RAR is growth inhib-
itory (20–22).
RAR2 expression, like RAR2, is induced by RA through
the DR5 element in the RAR2 promoter, which is remark-
ably conserved with that of RAR2 (23). We showed earlier
that RAR2 expression is down-regulated in several human
breast cancer cell lines relative to normal breast fibroblasts
(24). However, the possible significance of this observation
has been masked by the fact that most breast cancer cells Received 1/7/02; revised 4/26/02; accepted 6/17/02.
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enchymal cells as reference.
We have now analyzed RAR1, RAR2, and RAR2 ex-
pression in MCF-7 cells relative to immortalized but nontu-
morigenic MTSV1–7 human breast ductal epithelial cells.
Furthermore, we studied the growth effects of ectopic
RAR2 as compared with RAR2 and analyzed the methyl-
ation status of the endogenous RAR2 promoter. In aggre-
gate, our results suggest that RAR2 down-regulation con-
tributes to the impaired RA responsiveness of cancer cells.
Results
RAR Expression in MCF-7 Cells Relative to Established
Nontumorigenic Breast Epithelial Cells. We compared
and contrasted RAR2 expression in tumorigenic MCF-7
and nontumorigenic MTSV1–7 breast epithelial cells with the
expression of RAR1 and RAR2 in the same cell pair.
MTSV1–7 cells expressed both RAR2 and RAR2 under
basal conditions, and expression levels increased on treat-
ment with 1 M RA, as expected (Fig. 1A). Similar results
were obtained for HMEC cultures generated from reduction
mammoplasty tissue and enriched in luminal cells (Fig. 1B).
In contrast, neither RAR2 nor RAR2 expression could be
detected in MCF-7 cells even after treatment with 1 M RA
(Fig. 1A). Thus, RAR2 mirrors the expression pattern of
RAR2. On the other hand, both MTSV1–7 and MCF-7 cells
expressed RAR1, but expression levels were clearly higher
in MCF-7 cells (HMECs expressed RAR1 at levels compa-
rable with those of MTSV1–7 cells, data not shown). This is
because MTSV1–7 cells, like most of the normal breast ep-
ithelium but unlike MCF-7 cells, do not express ER (25),
which is known to up-regulate RAR1 transcription (26).
These results suggest that the total RAR mRNA concentra-
tion (1  2) in MCF-7 cells is comparable with that of
MTSV1–7 cells. However, when considering only RAR2 ex-
pression, the pattern is analogous to the loss of RAR2
expression in MCF-7 breast cancer cells.
We next performed Western blot analysis to compare
RAR and RAR protein expression in MTSV1–7 and MCF-7
cells. Antibodies against the F domain of RAR (recognizing
both RAR1 and 2) or RAR (likewise recognizing multiple
subtypes) were used. The slightly shorter RAR2 protein
migrates sufficiently ahead of RAR1 to allow unambiguous
identification of each receptor subtype (27). Interestingly,
despite the RT-PCR differences described above, RAR1
protein levels were essentially the same in MTSV1–7 and
MCF-7 cells (Fig. 1C). In sharp contrast, RAR2 was ex-
pressed in RA-treated MTSV1–7 but not in RA-treated
MCF-7 cells, and its expression level was comparable with
that of RAR1. These results suggest that the total RAR
protein concentration (1   2) in MCF-7 cells is 50%
lower than in nontumorigenic cells. Like RAR2, RAR was
detected only in MTSV1–7 cells; its expression was evident
under basal conditions but increased after RA treatment (Fig.
1C). On the basis of the lack of RAR1 expression in the
breast and the good agreement between relative RAR2
mRNA (Fig. 1A) and RAR protein expression levels (Fig. 1C),
we suspect that the band detected by the anti-RAR anti-
body corresponds to RAR2.
In sum, nontumorigenic MTSV1–7 cells express both
RAR2 and RAR2 mRNA and RAR2 and RAR protein,
whereas MCF-7 tumor cells fail to express these inducible
receptors.
Mechanism Underlying RAR2 Silencing in MCF-7
Cells. The RAR2 promoter and 5-UTR region are highly
CpG rich. This is actually in contrast to the same region of the
RAR2 gene, which is CpG poor. Nevertheless, there is good
evidence that hypermethylation of the RAR2 promoter and
5-UTR is the proximal cause of RAR2 underexpression in
MCF-7 cells (11). We, therefore, analyzed the methylation
Fig. 1. RA receptor expression in human breast epithelial cells. A, semiquantitative RT-PCR analysis of RAR1, RAR2, and RAR2 expression in
immortalized nontumorigenic MTSV1–7 cells and MCF-7 breast carcinoma cells under basal conditions (Lanes labeled C) and after treatment with 1 M RA
for 24 h (Lanes labeled RA). The results shown are representative of at least three experiments. The first and second panels from the top, ethidium bromide
staining and RT-PCR Southern data, respectively, for RAR 1 and RAR2 (see “Materials and Methods” for details of coamplification and unambiguous
identification of each amplicon). The low but detectable RAR1 expression in MTSV1–7 cells was more readily apparent in experiments in which RAR1
was amplified separately (not shown). The third and fourth panels, RAR2 and GAPDH RT-PCR Southern data, respectively. B, semiquantitative RT-PCR
Southern analysis of RAR2 (RAR1 primer not included) and RAR2 expression in primary normal HMECs enriched in luminal cells; the ethidium bromide
signal for GAPDH is shown to demonstrate even loading. RA treatment was as in A. Expression of RAR2 and RAR2 was confirmed in a second cell
preparation. C, Western blot analysis of RAR and RAR expression in MTSV1–7 and MCF-7 cells under basal conditions and after RA treatment as in A
(see “Materials and Methods” and “Results” for details).
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results (Fig. 2A) demonstrated uniform and highly penetrant
methylation of the region studied. This includes three CpG
sites near the DR5 response element (highlighted in Fig. 2A),
which are conserved and also methylated in the RAR2
promoter in MCF-7 cells. We have proposed that methylation
of these sites may be particularly relevant to promoter si-
lencing (28).
To test whether hypermethylation contributes to RAR2
silencing, we pretreated exponentially growing MCF-7 cells
with azaC, which is incorporated into DNA and inhibits DNA
methyltransferase. Three days later, we treated the cells with
a combination of RA and TSA, a histone deacetylase inhib-
itor; control cultures were pretreated with growth medium
alone and then treated as above. As shown in Fig. 2B, MCF-7
cells, pretreated with azaC and then treated with RA and
TSA, expressed readily detectable amounts of RAR2 mes-
sage, whereas the same treatment had no effect in cells not
pretreated with azaC. Bisulfite sequencing of DNA isolated
from cultures pretreated with azaC and then treated with RA
and TSA revealed a modest and variable degree of RAR2
promoter demethylation (Fig. 2A). We suspect that more
extensive demethylation occurred in a small fraction of cells
and that RAR2 reexpression in these cells accounted for
the RT-PCR signal detected in Fig. 2B. Alternatively, a mod-
est degree of demethylation may be sufficient to initiate
chromatin remodeling. These results implicate RAR2 hy-
permethylation as a proximal cause of RAR2 silencing in
MCF-7 cells.
RAR2 Is a Growth Suppressor. We wished to compare
the effect on cell growth of the ectopic expression of
matched levels of RAR2 and RAR2. To this end, we con-
structed a bicistronic mammalian expression vector encod-
ing RAR2o rR A R 2 and EGFP (pRAR2-IRES-2-EGFP and
RAR2-IRES-2-EGFP, respectively). Our goal was to use
EGFP to infer RAR expression levels rather than rely on the
use of antibodies with different titer and affinity. Preliminary
experiments demonstrated that transfection of MCF-7 cells
Fig. 2. The human RAR2 promoter is hyper-
methylated in MCF-7 breast carcinoma cells.
A, bisulfite sequencing of the RAR2 pro-
moter. The region analyzed is sketched (top),
showing CpG sites (tick marks), the approxi-
mate position of the primers used (horizontal
arrows) and the three CpG sites in the RARE
(bracket) region. The RAR2 sequence
(gi:9392669) was numbered relative to the
transcription start site. Bisulfite sequencing re-
sults (bottom) are shown for each clone ana-
lyzed (F, methylated CpGs; E, unmethylated
CpGs). Top panel, results for untreated cells;
bottom panel, results for cells pretreated with
azaC and treated with RA and TSA (see be-
low); cells not pretreated with azaC and
treated with RA and TSA yielded results similar
to those for untreated cells (data not shown).
B, semiquantitative RT-PCR analysis of
RAR2 expression in untreated MCF-7 cells
(Lane 1), cells treated with 1 M RA and 100 nM
TSA for 24 h (Lane 2), and cells pretreated with
5 M azaC for 72 h and then treated with 1 M
RA and 100 nM TSA for 24 h (Lane 3).
337 Cell Growth & Differentiationwith a fixed amount of vector (2 g) resulted in the same
overall expression level of EGFP and, thus, by inference, of
RAR2 and -2 (Fig. 3A). For the experiment proper, we
transfected MCF-7 cells with the same fixed dose of each
vector and, as a control, 2 go fa n“empty” (no RAR insert)
bicistronic vector (pIRES-2-EGFP). Fig. 3B shows the pattern
of EGFP fluorescence of parallel cultures transfected as
above and selected in G418 in the absence of RA; compa-
rable fluorescent signals were obtained for each cell group.
The experimental cultures were placed in selection medium
with or without RA supplementation and colonies allowed to
grow for a period of 3 weeks. All of the groups of transfected
cells formed multiple colonies in selection medium without
RA. Treatment with 10 and 20 nM RA had a minimal effect on
the clonogenic potential of control, pIRES-2-EGFP-trans-
fected cells (Fig. 4A). In contrast, the same treatment had a
marked inhibitory effect on the clonogenic potential of
pRAR2-IRES-2-EGFP- and RAR2-IRES-2-EGFP-trans-
fected cells. More importantly, the magnitude of this effect,
as can be seen visually (Fig. 4A) and after colorimetry (Fig.
4B), was comparable for RAR2 and -2. We conclude that
RAR2, like RAR2, is a growth suppressor. This conclusion
is based on the interpretation that the results obtained were
attributable to the transfected RAR2 and -2 receptors per
se and not to secondary effects on other nuclear receptors.
Discussion
Our findings need to be discussed within the context of the
prevailing idea that down-regulation of RAR2 may specifi-
cally contribute to cancer progression. Although this is an
attractive idea, recent developments have revealed a more
complex scenario. For instance, breast cancer cells can ex-
press the RAR4 isoform, which may act as a dominant
Fig. 4. Comparable inhibition of MCF-7 clonogenic growth by RAR2
and RAR2. MCF-7 cells were transfected with 2 g of pIRES-2-EGFP,
pRAR2-IRES-2-EGFP, or pRAR2-IRES-2-EGFP and then plated at low
density in selection medium supplemented with charcoal-stripped serum
and the indicated concentration of RA. A, crystal violet-stained cultures
after 3 weeks in selection medium. For each plate, wells within the same
column represent triplicates. B, densitometric evaluation of cell number in
the cultures shown in A. Similar results to those shown were obtained in
two additional experiments.
Fig. 3. Transgene expression in transfected MCF-7 cells. MCF-7 cells
were transfected with bicistronic expression vectors [RAR and EGFP
under the control of the cytomegalovirus (CMV) promoter], stable trans-
fectants selected in the absence of RA, and EGFP protein assayed to infer
RAR expression levels. A, Western blot analysis showing similar overall
EGFP expression levels after stable transfection with equal amounts (2 g)
of pRAR2-IRES-2-EGFP and pRAR2-IRES-2-EGFP. To verify that the
CMV promoter was not RA dependent, EGFP expression was also mon-
itored after 24-h treatment with 1 M RA; this had no effect on EGFP
expression, as expected. B, fluorescence microscopy (EGFP autofluores-
cence) of MCF-7 cultures transfected as in A and, as a control, transfected
with 2 g of pIRES-2-EGFP vector. The fluorescent signals produced by
the three cell groups are similar.
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over RAR2 (29). A recent study of RAR2 mRNA as a
prognostic indicator in non-small cell lung cancer actually
demonstrated decreased disease-free survival in RAR2-
expressing cases (30). These findings reflect the complexity
of RAR signaling. In the context of breast cancer, we have
now introduced an additional element of complexity by dem-
onstrating that the thus-far-overlooked RAR2 congener,
RAR2, can function as an RA-dependent growth suppres-
sor. Our results suggest that RAR2, besides being RA-
inducible, shares three properties with RAR2: it is under-
expressed in MCF-7 cells relative to normal and
nontumorigenic cells, it is epigenetically silenced, and its
product acts as a growth suppressor. We, therefore, suggest
that RAR2 should be considered as a factor of equal im-
portance to RAR2 in studies of aberrant RAR expression
and function in breast cancer and perhaps other cancers as
well.
Although homozygous deletion of RAR2 has been shown
to impair RA-induced growth arrest in F9 cells (31), and mice
harboring an RAR2 antisense transgene have been shown
to develop lung tumors (32), similar studies with RAR2 have
not been reported. On the other hand, several studies have
shown that ectopic RAR1 is growth suppressive (18, 19)
and that selective RAR ligands are growth inhibitory (20–
22). Interestingly, it has been proposed that the ability of
RAR1 to restore RA growth regulation in ER-nonexpress-
ing breast cancer cells is secondary to the induction of
RAR2 (17). However, induction of RAR2 likely occurred
under the same conditions because they have conserved
promoters (23). In this context, it is interesting to point out
that the recent demonstration that constitutively expressed
RAR protein (i.e., RAR1) is rapidly down-regulated after
RA activation (33, 34) suggests that the induction of RAR2
and RAR2 may be critical for sustaining a RA response.
Undoubtedly, the best way to dissect the relative contribu-
tion of each isoform would be to extend the targeted gene
deletion approach undertaken in F9 cells (31) to a diploid
breast cell line that is sensitive to RA-induced growth arrest.
An in situ hybridization study by Xu et al. (8) demonstrated
that RAR (total) mRNA is undetectable in 16% of invasive
human breast cancers as compared with 2% of normal
breast tissues. Taking into account that RAR1 mRNA levels
in nontumorigenic ER-nonexpressing cells (MTSV1–7) ap-
proximate those in ER-nonexpressing breast cancer cells
(i.e., they are detectable but lower than the levels expressed
by ER-expressing cells; Fig. 1A; Ref. 21), we hypothesize
that the RAR down-regulation detected by Xu et al. repre-
sents down-regulation of RAR2 (the true extent of RAR2
down-regulation may in fact be greater). An in situ hybrid-
ization study using RAR1- and RAR2-specific riboprobes
is needed to test this hypothesis and reveal the extent, if any,
of in situ RAR2 down-regulation in breast cancer.
The evidence implicating aberrant RAR expression in can-
cer remains largely circumstantial, and this report is no ex-
ception. Further progress might be achieved, for instance,
through a study of RAR methylation and expression in ex-
isting mouse models of breast cancer, which afford the op-
portunity to sample tissues at linear time points. RAR isoform
and subtype-specific knockout mice represent another op-
portunity for progress.
Materials and Methods
Cells. The MCF-7 breast cancer cell line was obtained from
the American Type Culture Collection (Rockville, MD) and
grown in DMEM supplemented with 10% FBS, 5 g/ml in-
sulin, and antibiotics (100 units/ml penicillin and 100 g/ml
streptomycin). MTSV1–7 is a SV40 T-antigen-immortalized,
nontumorigenic human breast ductal epithelial cell line that
was generated, kindly donated, and maintained as de-
scribed, by Joyce Taylor-Papadimitriou (The Imperial Cancer
Research Fund, Guy’s Hospital, London, England) and col-
leagues [Bartek et al. (35)]. Because late-passage MTSV1–7
cells exhibit properties of transformed cells (data not shown),
we used early-passage cells in the present studies. Both of
the cell lines were tested for Mycoplasma by DAPI staining
and shown to be free of contamination.
Normal HMECs were derived from reduction mammo-
plasty material that was residual to pathologic analysis and
bore no identifiers. After obtaining epithelial organoids as
described previously (36), enrichment in luminal cells was
performed by negative immuno-selection (37) and the cells
cultured in collagen I-coated dishes in mammary epithelium
growth medium (Clonetics, San Diego, CA) supplemented
with 5 g/ml transferrin and 10 M isoproterenol (cells were
used after 0–1 passages).
RT-PCR Analysis. Aliquots of 1 g of total RNA were
reverse transcribed in 20-l reaction volumes using the
SuperScript Preamplification System (Life Technologies, Inc.
Gaithersburg, MD). The PCR mixture consisted of 10 PCR
buffer [200 mM Tris-HCl (pH 8.4), 500 mM KCl], 1 mM MgCl2,
200 M dNTPs, 0.4 M each primer, 2 l cDNA, and 5 units
of Taq (Promega) in a total volume of 50 l. Primers for the
amplification of RAR1 and -2 were as described previ-
ously (38), and cycling parameters were: 94°C for 5 min; 30
cycles of 94°C for 1 min, 60°C for 1 min, 72°C for 1 min; and
72°C for 5 min. RAR1 and -2 were amplified, separately or
in the same reaction, using sense primers that anneal to the
A1 or A2 region, respectively, and an antisense primer that
anneals to the common B region, yielding products of 220 bp
and 287 bp, respectively. PCR products (25 l aliquots) were
separated in 1.5% agarose gels, blotted, and hybridized to
probes labeled with [
32P]dCTP by random priming. The
RAR1 amplification product was detected using an autol-
ogous probe (this was validated by probing with full-length
RAR1 cDNA) and the RAR2 product was detected using
full-length RAR2 cDNA. When RAR1 and -2 were ampli-
fied in the same reaction, the two products were detected by
hybridization to full-length RAR2 cDNA and could be un-
ambiguously identified based on their different sizes (sepa-
rate amplification reactions validated the results obtained
after coamplification). RAR2 and GAPDH RT-PCR were
performed as described previously (28).
Western Blot Analysis. Cells were lysed on ice for 30 min
with radioimmunoprecipitation assay buffer (1 PBS, 1%
NP40, 0.5% sodium deoxycholate, and 0.1% SDS) plus pro-
teinase inhibitors (1 mM phenylmethylsulfonyl fluoride, 1
g/ml aprotinin, 1 g/ml leupeptin, and 1 g/ml pepstatin)
339 Cell Growth & Differentiationand phosphatase inhibitors (1 mM Na3VO4 a n d1m M NaF); for
more efficient cell lysis, the samples were frozen (80°C) and
thawed once. Protein was quantitated by the method of
Bradford (39) and 50 g of total protein/lane were resolved
by SDS-PAGE (10% polyacrylamide). Rabbit polyclonal an-
tibodies raised against the F region of RAR (number 115)
was a generous gift from Pierre Chambon (Institut de Gene-
tique et de Biologie Moleculaire et Cellulaire, Strasbourg,
France); rabbit polyclonal antibodies raised against the F
region of RAR (C-19) were obtained from Santa Cruz Bio-
technology. Polyvinylidene difluoride membranes were
blocked with TBST plus 5% milk for 1 h and incubated with
first antibody diluted to 1 g/ml in TBS plus 1% milk for 1 h
at room temperature. The membranes were washed five
times with TBST and once with TBS and treated with sec-
ondary antirabbit antibody diluted to 0.3 g/ml in TBS plus
1% milk for 45 min at room temperature. The membranes
were then washed as above and reaction products visualized
using Amersham’s chemiluminiscence detection system.
For EGFP expression, total cell lysates were resolved by
SDS-PAGE and probed with EGFP antibodies obtained from
Clontech (Palo Alto, CA).
Bisulfite Sequencing. Briefly, 5 go fXbaI-digested
genomic DNA was denatured with 0.5 M NaOH at 75°C for 15
min, deaminated with freshly prepared 4.0 M (pH 5.0) sodium
metabisulfite (BDH Laboratory Supplies, Poole, Dorset,
England) and incubated at 55°Cf o r8hi natotal volume of
1.2 ml under mineral oil. Desalting, desulfonation by alkali,
neutralization, and ethanol precipitation were as described
previously (40); the DNA was resuspended in 50 lo fH 2O.
First-round PCR was carried out in a 50-l reaction mixture
of 10 PCR buffer, 1.2 mM MgCl2, 160 M dNTPs, 0.4 M
each primer, 10 l bisulfite-treated DNA, and 5 units of Taq
(Promega). Subsequently, two rounds of seminested PCR
were carried out using the same conditions as above and 5
l of the reaction product generated in the preceding
round as template. Primers and parameters were: 5-
TTAGGGATTTATTTAAGTTAGGTTTTTT-3 (sense) and 5-
AACTCCCCCAAAATTTAATCAATCCCTAAC-3 (anti-
sense); 94°C for 5 min; 40 cycles of 94°C for 1 min, 48°C
for 1 min, 72°C for 1 min; 72°C for 5 min. Primers and
parameters for the second round were: 5-TTTTTGTTTGT-
GTTTGTGTTAATAGTATT-3 (sense) and the same antisense
as above with parameters as above, except annealing tem-
perature was 46°C, and the reaction was terminated after 20
cycles. Third round primers and parameters were: 5-
TATATATATGTTATAGATAATGATAT-3 (sense) and the
same antisense as above; parameters were the same as for
second round parameters but for 40 cycles. The purified
PCR fragment was subcloned into pCR2.1, and individual
clones were submitted for sequencing (T7 primer).
Cell Transfection. Monolayers of MCF-7 cells at
70–80% confluence were transfected (FuGene system,
Roche) with 2 g of pIRES-2-EGFP vector alone or carrying
full-length RAR2o rR A R 2 cDNA inserts. Two days later,
the cells were trypsinized and plated at the desired concen-
tration in selection medium (800 g/ml Geneticin). Mock-
transfected MCF-7 cells were used to follow cell selection
and transfection efficiency was monitored by fluorescence
microscopy.
RA Treatment. For testing the effect of 1 M RA on RAR
expression, cells in regular growth medium were treated with
RA for 24 h and harvested for analysis. For testing the effect
of low RA doses on MCF-7 clonogenicity, FBS was charcoal
stripped as follows: 1.25 g of activated charcoal and 0.125 g
of dextran T-70 were added to a 500-ml FBS bottle followed
by incubation at 55°C for 30 min and centrifugation at 3000
rpm at 4°C for 20 min. The resulting single-stripped serum
was collected into a fresh 500-ml flask and the procedure
repeated with a second round of charcoal-dextran, but in-
cubated at 37°C for 30 min and, finally, sterile-filtered.
MCF-7 breast cancer cells transfected as above were
seeded in 6-well (5  10
4 cells/well) or 12-well (2  10
4
cells/well) plate dishes in medium supplemented with 10%
charcoal-stripped FBS, 5 g/ml insulin, 800 g/ml Geneticin,
and antibiotics. After 3 weeks, Geneticin-resistant colonies
were fixed in 10% formalin in PBS and stained with 0.05%
crystal violet. After photography, the stain was solubilized
with 10% acetic acid-10% methanol, and the A595 was
measured to quantitate adherent cell mass.
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